Genotype distribution and minor allele frequency (MAF) of TRAF6 rs540386 in systemic sclerosis (SSc) and giant cell arteritis (GCA) patients according to the presence or absence of specific clinical manifestations.
| With Manifestations | Without Manifestations | Allele Test | ||||
|---|---|---|---|---|---|---|
| Manifestation | Genotypic Frequencies | MAF, % | Genotypic Frequencies | MAF, % | p** | OR (95% CI)*** |
| SSc | ||||||
| SSc subtype* | 3/74/290 | 10.90 | 14/170/634 | 12.10 | 0.400 | 0.89 (0.67–1.17) |
| Anticentromere antibodies | 9/111/425 | 11.83 | 7/125/465 | 11.64 | 0.886 | 1.02 (0.79–1.32) |
| Antitopoisomerase antibodies | 1/52/206 | 10.42 | 14/178/662 | 12.06 | 0.310 | 0.85 (0.62–1.17) |
| Pulmonary fibrosis | 4/59/223 | 11.71 | 11/170/623 | 11.94 | 0.885 | 0.98 (0.73–1.32) |
| GCA | ||||||
| Polymyalgia rheumatica | 1/46/166 | 11.27 | 3/62/192 | 13.23 | 0.363 | 0.83 (0.56–1.24) |
| Visual ischemic manifestations | 0/30/100 | 11.54 | 4/78/255 | 12.76 | 0.612 | 0.89 (0.57–1.39) |
| Severe ischemic manifestations | 1/58/183 | 12.40 | 3/50/170 | 12.56 | 0.941 | 0.99 (0.67–1.46) |
| Irreversible occlusive disease | 0/16/69 | 9.41 | 4/85/269 | 12.99 | 0.202 | 0.70 (0.40–1.22) |